Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-escalation study of AZD9773 in Japanese patients with severe sepsis and/or septic shock
jRCT2080221164Phase 2
- Sponsor
- AstraZeneca
- Start
- Jul 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD9773 in sepsis and septic shock (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD9773 and Pharmacokinetics of AZD9773.
02
Drugs
AZD9773
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on jRCT2080221164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221164.